Innate Pharma
IPHA
12 hedge funds and large institutions have $49.7M invested in Innate Pharma in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
9.82% more ownership
Funds ownership: 0% → 9.82% (+9.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$27.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.32M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.23M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$799K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EC
1
EcoR1 Capital
San Francisco,
California
| $29.3M | +$27.9M | +4,545,454 | New |
|
|
2
Wellington Management Group
Boston,
Massachusetts
| $8.71M | +$8.32M | +1,353,773 | New |
|
|
RCMNY
3
Rubric Capital Management (New York)
New York
| $8.69M | +$8.3M | +1,350,000 | New |
|
|
4
Adage Capital Partners
Boston,
Massachusetts
| $1.29M | +$1.23M | +200,000 | New |
|
|
MS
5
Maven Securities
St Helier,
Jersey
| $836K | +$799K | +130,000 | New |
|
6
Millennium Management
New York
| $477K | +$456K | +74,242 | New |
|
|
OAM
7
Oxford Asset Management
Oxford,
United Kingdom
| $284K | +$272K | +44,226 | New |
|
|
OMC
8
Old Mission Capital
Chicago,
Illinois
| $84K | +$80.1K | +13,038 | New |
|
|
FIA
9
FNY Investment Advisers
New York
| $11K | +$11K | +1,795 | New |
|
|
SPIA
10
Steward Partners Investment Advisory
New York
| $7K | +$6.76K | +1,100 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $6K | +$5.76K | +937 | New |
|
|
LTFS
12
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | +$92 | +15 | New |
|
IPHA Hedge Fund Activity: Q4 2019 in Review
12 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2019, worth a combined $49.7M.
Buyers outnumbered sellers: 12 funds opened new IPHA positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $27.9M.
- 12 institutional investors held Innate Pharma (IPHA) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $49.7M of Innate Pharma stock for Q4 2019.
- 12 funds opened new Innate Pharma positions in Q4 2019 and 0 closed out, a net change of +12 holders.
- The largest Innate Pharma buyer in Q4 2019 was EcoR1 Capital, an estimated $27.9M added.
Based on aggregated 13F filings for Q4 2019.